Pilot randomized, non-inferiority, cross-over trial of once-weekly vs. three times-weekly recombinant factor VIII prophylaxis in adults with severe haemophilia A
Haemophilia
.
2017 Jan;23(1):e43-e46.
doi: 10.1111/hae.13131.
Epub 2016 Dec 11.
Authors
M V Ragni
1
2
,
J G Yabes
3
,
P F Fogarty
4
,
N C Josephson
5
,
C M Kessler
6
,
A T Neff
7
,
L Raffini
8
,
K Brummel-Ziedins
9
,
C G Moore
3
Affiliations
1
Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
2
Hemophilia Center of Western Pennsylvania, Pittsburgh, PA, USA.
3
Center for Research on Health Care Data Center, University of Pittsburgh, Pittsburgh, PA, USA.
4
University of Pennsylvania, Philadelphia, PA, USA.
5
Puget Sound Blood Center, Seattle, WA, USA.
6
Georgetown University Medical Center, Washington, DC, USA.
7
Vanderbilt University Medical Center, Nashville, TN, USA.
8
Children's Hospital of Philadelphia, Philadelphia, PA, USA.
9
Department of Biochemistry, University of Vermont, Colchester, VT, USA.
PMID:
27943502
PMCID:
PMC5226871
DOI:
10.1111/hae.13131
No abstract available
Publication types
Letter
Randomized Controlled Trial
MeSH terms
Cross-Over Studies
Factor VIII / therapeutic use*
Hemophilia A / drug therapy*
Humans
Male
Pilot Projects
Substances
Factor VIII
Grants and funding
R34 HL105870/HL/NHLBI NIH HHS/United States